Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2012

View Archived Issues

New MMP inhibitors designed

Scientists in Germany patent novel HSP 90 inhibitors

Merck & Co. prepares novel HCV inhibitors

New transient receptor potential TRPM8 channel antagonists patented

Novel phosphodiesterase 10A inhibitors presented by Merck & Co.

Novel histamine H4 receptor ligands designed in France

Enanta presents novel antiviral with excellent cross-resistance profile

New Roche oncolytic targets chondroitin sulfate proteoglycan 4

BAF-312 dose titration reduces bradyarrhythmic events in phase II trial

Phase I data encourage advancement of candidate MS drug to phase II

MicroDose Therapeutx completes phase I studies of MDT-637

Omontys launched in U.S.

Alimera announces first marketing authorization for Iluvien in E.U.

Bayer expands BiTE antibody collaboration

Recruitment complete in phase II studies of Levulan Kerastick PDT

New Presidio product shows promise to treat hepatitis

Nordion plans new phase III TheraSphere trial

Summit clear to conduct phase I trial of SMT-C1100

Adocia reports phase II results for diabetic foot ulcer treatment

Nanobody for Alzheimer's disease advances toward phase I trials

NICE issues final guidance on new hepatitis C drugs

Recommendations issued for treatment of first-line chronic myeloid leukemia

NICE recommends NHS provide Gilenya in relapsing-remitting MS

Hisamitsu reports on HTU-520 study

First medicine approved in E.U. for Cushing's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...